Article
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.
Nature medicine - 1 Mar 2026
Lee Holly, Ahn Sungwoo, Gonzales Gerone A, Leblay Noemie, Barakat Elie, Greening Dylan, Colarusso Pina, Canton Johnathan, Benaoudia Sacha, Hasheminasabgorji Elham, Poorebrahim Mansour, Jung David, Truger Marietta, Jeong Jihong, Riedhammer Christine, Einsele Hermann, Kortüm K Martin, Eckmann Jan, Somandin Jitka, Engel Sara-Sheena, Boise Lawrence H, Frenking Jan Hendrik, Weinhold Niels, Taouxi Konstantina, Kastritis Efstathios, Skerget Sheri, Vishwamitra Deeksha, Cho Yunje, Maura Francesco, Raab Marc S, Corre Jill, Rasche Leo, Avet-Loiseau Hervé, Neri Paola, Bahlis Nizar J
Abstract excerpt
Tumor-intrinsic adaptations with emerging resistant clones following T cell-targeted immunotherapies pose a major barrier to durable remissions in multiple myeloma. Through integrated genomic, transcriptomic and epigenomic interrogation of clonal plasma cells, we observed antigenic drift in 68.4% of relapsed cases following anti-GPRC5D T cell-engager (TCE) therapy (n = 21). These escape events were driven by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.